Hormonal
Tirzepatide induces significant, dose-dependent weight loss in patients with obesity or type 2 diabetes, with non-diabetic individuals experiencing greater absolute weight reduction than diabetic individuals at equivalent doses.
Tirzepatide is a highly effective treatment for weight loss, with higher doses (15 mg) producing the greatest results. Non-diabetic patients tend to lose more weight than diabetic patients at the same dose. The most common barrier is gastrointestinal side effects like nausea, which are dose-dependent but typically manageable and do not lead to serious health risks.
Tirzepatide induced a mean weight reduction of –10.39 kg versus placebo... Subgroup analyses by diabetes status showed that patients with type 2 diabetes lost –6.17 kg... at 5 mg... Non-diabetic participants experienced greater absolute losses of –12.10 kg... at the respective doses.
Why this rating
The claim is based on a systematic review and meta-analysis of 11 randomized controlled trials (Phase 1-3) involving diverse populations, published in high-impact journals.
Source
Efficacy and safety of tirzepatide for weight loss in patients with obesity or type 2 diabetes: a systematic review and meta-analysis
Qiru Tian et al. · Frontiers in Endocrinology · 2025
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →